PASG (Passage Bio) Moat Score: 3/10 (As of Jul. 03, 2026)


PASG Passage Bio Inc PASG
30 GF Score
Price $4.63
! 2 Warning Signs
View Full Analysis

What is Passage Bio Moat Score?

Passage Bio PASG +2.18% 30 Moat Score is 3 as of Jul. 03, 2026. GuruFocus rates PASG with a GF Score™ of 30/100. The stock has 2 warning signs investors should review. Among 1,399 Biotechnology companies, Passage Bio ranks better than 75.48% on this metric.

Passage Bio has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Passage Bio has No Moat: Passage Bio operates in a highly competitive biotech sector with limited market leadership and no significant customer switching costs. While it may have valuable IP, the transient nature of biotech advantages and lack of a strong brand or distribution network result in a very weak moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Passage Bio might have No Moat - Very weak/transient advantages.

Passage Bio  (NAS:PASG) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Passage Bio Moat Score Related Terms

PASG vs CTXR, HIND, GTBP: Moat Score Comparison

For the Biotechnology subindustry, Passage Bio's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Passage Bio Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Passage Bio's Moat Score distribution charts can be found below:

* The bar in red indicates where Passage Bio's Moat Score falls into.


PASG
30GF Score
Passage Bio Inc PASG
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Passage Bio (PASG) has a Moat Score of 3 as of Jul. 03, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Passage Bio ranks #343 out of 1399 companies in the Biotechnology industry, placing it in the top 24.5%.
Is Passage Bio's Moat Score too high?
Passage Bio's current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. Passage Bio's value of 3 is 50% above this industry median. Based on the distribution chart, Passage Bio ranks #343 out of 1399 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Passage Bio has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Passage Bio's Moat Score compare to CTXR and HIND?
According to the Biotechnology industry distribution chart, Passage Bio ranks #343 out of 1399 companies for Moat Score. This places Passage Bio in the top 25% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Passage Bio's value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,399 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Passage Bio's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Passage Bio's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Passage Bio stock overvalued right now?
Passage Bio (PASG) has a current Moat Score of 3. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. Passage Bio's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Passage Bio (PASG), the current Moat Score is 3 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Passage Bio Business Description

Address 2005 Market Street, 39th Floor, One Commerce Square, Philadelphia, PA, USA, 19103
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.
30GF Score

Get the complete analysis for PASG

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.63
Price